Innovation Pharmaceuticals Inc. (IPIX)
Market Cap | 85.21M |
Revenue (ttm) | 23,000 |
Net Income (ttm) | -6.27M |
Shares Out | 337.49M |
EPS (ttm) | -0.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 13 |
Last Price | $0.1755 |
Previous Close | $0.1800 |
Change ($) | -0.0050 |
Change (%) | -2.50% |
Day's Open | 0.1725 |
Day's Range | 0.1710 - 0.1837 |
Day's Volume | 827,436 |
52-Week Range | 0.053 - 0.65 |
News
Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent ...
About IPIX
Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Ch... [Read more...]
Industry Biotechnology | |
CEO Leo Ehrlich | Employees 4 |
Stock Exchange OTCMKTS | Ticker Symbol IPIX |